Deep-sea natural compound targets cancer cells through a dual mechanism
Why it matters: A deep‑sea sponge compound could become a next‑generation, cancer‑specific therapy.
- Yaku'amide B exploits a dual mechanism—mitochondrial dysfunction and PI3K/AKT inhibition—to induce cancer cell death (Nature paper, 2024)
- International research consortium (University of Tokyo, MIT, and a biotech startup) confirmed selective toxicity in vitro and tumor regression in mouse xenografts (press release, 2024)
- Independent commentary (BioTech Insight) highlights the novelty of targeting two pathways with a single natural product, noting the challenge of translating deep‑sea chemistry into scalable drugs
Researchers have revealed that yaku'amide B, a rare peptide from a deep‑sea sponge, kills cancer cells through a two‑pronged attack—disrupting mitochondrial metabolism and blocking a key oncogenic signaling pathway. The dual mechanism yields high selectivity for tumor cells and shows potency across several cancer models, positioning the compound as a promising pre‑clinical drug candidate.
